DNA-damaging drug-induced apoptosis sensitized by N-myc in neuroblastoma cells

Cell Biology International

Volumn 36, Issue 4, 2012, Pages 331-337

  Li, Tai ^a   Wang, Lin ^b   Ke, Xiao Xue ^a   Gong, Xue Yang ^a   Wan, Jian Hua ^a   Hao, Xiang wei ^a   Xu, Man ^a   Xiang, Zonghuai ^a   Cui, Zhao Bo ^c   Cui, Hongjuan ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b Beijing Entry Exit Inspection and Quarantine Bureau   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Caspase 9; DNA damaging drug; N myc; p53; SHEP1 cell

Indexed keywords

ARGININE; CASPASE 9; DNA; DNA FRAGMENT; DOXORUBICIN; ENHANCED GREEN FLUORESCENT PROTEIN; ETOPOSIDE; HISTIDINE; MYC PROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DRUG INDUCED DISEASE; ENZYME ACTIVATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE MYC; PATHOGENESIS; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 9; CELL LINE, TUMOR; CHILD; DNA FRAGMENTATION; DNA, NEOPLASM; DOXORUBICIN; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-MYC; RETROVIRIDAE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859237670     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20110231     Document Type: Article

References (66)

1. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild-type p53 activity. EMBO J 1993;12:461-8.
2. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998;395:124-5.
3. Bellodi C, Kopmar N, Ruggero D. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J 2010;29:1865-76.
4. Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002;2:377-86.
5. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
6. Brodeur G, Gastleberry R. Neuroblastoma. In: Pizzo P, Poplack D, editors. Principles and Practice of Pediatric Oncolgy, 3rd edn. Philadelphia: Lippincott-Raven Publishers 1997. p. 761-97.
7. Brown JP, Pagano M. Mechanism of p53 degradation. Biochim Biophys Acta 1997;1332:O1-6.
8. Chattopadhyay P, Chaudhury P, Wahi AK. Bcl-2 expression alters the mitochondrial tri carboxyl acid pathway in hepatic ischemic and reperfusion induced necrosis and apoptosis in rat liver. Indian J Pharm Sci 2010;72:437-41.
9. Costa C, Rocha G, Grilo M, Bianchi R, Sotto Mayor T, Monteiro J, et al. Neonatal tumors. Acta Med Port 2010;23:405-12.
10. Di Carlo M, Picone P, Carrotta R, Giacomazza D, San Biagio PL. Insulin promotes survival of amyloid-beta oligomers neuroblastoma damaged cells via caspase 9 inhibition and Hsp70 upregulation. J Biomed Biotechnol 2010;2010:147835.
11. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
12. El-Sayed MI, Ali AM, Sayed HA, Zaky EM. Treatment results and prognostic factors of pediatric neuroblastoma: a retrospective study. Int Arch Med 2010;3:37.
13. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
14. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-40.
15. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57:3823-9.
16. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919-30.
17. Goldman SC, Chen CY, Lansing TJ, Gilmer TM, Kastan MB. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol 1996;148:1381-5.
18. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12.
19. Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998;94:339-52.
20. Hengartner M. The biochemistry of apoptosis. Nature 2000;407:770-6.
21. Herrmann M, Lorenz HM, Voll R, Grunke M, Woith W, Kalden JR. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 1994;22:5506-7.
22. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
23. How PC, Shields D. Tethering function of the caspase cleavage fragment of Golgi protein p115 promotes apoptosis via a p53-dependent pathway. J Biol Chem 2011;286:8565-76.
24. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999;13:2678-90.
25. Jasty R, Lu J, Irwin T, Suchard S, Clarke MF, Castle VP. Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells. Mol Genet Metab 1998;65:155-64.
26. Johnson KA, Aplenc R, Bagatell R. Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005. Pediatr Blood Cancer 2011;56:425-31.
27. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93.
28. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010;16:4583-94.
29. Kuida K, Haydar TF, Kuan C-Y, Gu Y, Taya C, Karasuyama H, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998;94:325-37.
30. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
31. Li T, Cui ZB, Ke XX, Tan J, Li FF, Wang XW, et al. Essential role for p53 and caspase-9 in DNA damaging drug-induced apoptosis in neuroblastoma IMR32 cells. DNA Cell Biol 2011;30:1045-50.
32. Li X, Zhao Y, Wu WK, Liu S, Cui M, Lou H. Solamargine induces apoptosis associated with p53 transcription-dependent and transcription-independent pathways in human osteosarcoma U2OS cells. Life Sci 2011;88:314-21.
33. Liu C, Wang Y, Xie S, Zhou Y, Ren X, Li X, et al. Liquiritigenin induces mitochondria-mediated apoptosis via cytochrome c release and caspases activation in HeLa Cells. Phytother Res 2011;25:277-83.
34. Liu XS, Kim CN, Yang J, Jemmerson R, Wang XD. Induction of apoptotic program in cell-free extracts-requirement for dATP and cytochrome c. Cell 1996;86:147-57.
35. Lutz W, Fulda S, Jeremias I, Debatin K-M, Schwab M. MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998;17:339-46.
36. Mallette FA, Calabrese V, Ilangumaran S, Ferbeyre G. SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence. Aging (Albany NY) 2010;2:445-52.
37. Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med 2011;3:64rv1.
38. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010;24:1580-9.
39. Marialaura P, Veschi V, Prodosmo A, Rinaldo C, Massimi I, Carbonari M, et al. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. Mol Cancer Res 2011;9:10.
40. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
41. McKenzie PP, Guichard SM, Middlemas DS, Ashmun RA, Danks MK, Harris LC. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res 1999;5:4199-207.
42. Mille F, Llambi F, Guix C, Delloye-Bourgeois C, Guenebeaud C, Castro-Obregon S, et al. Interfering with multimerization of netrin-1 receptors triggers tumor cell death. Cell Death Differ 2009;16:1344-51.
43. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312-25.
44. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
45. Neilsen PM, Pishas KI, Callen DF, Thomas DM. Targeting the p53 pathway in Ewing sarcoma. Sarcoma 2011;2011:746939.
46. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003;22:9007-21.
47. Ory D, Neugeboren B, Mulligan R. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 1996;93:11400-6.
48. Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002;12:309-15.
49. Ronca F, Chan SL, Yu VC. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine induces apoptosis in human neuroblastoma cells, SH-SY5Y, through a p53-dependent pathway. J Biol Chem 1997;272:4252-60.
50. Rovini A, Savry A, Braguer D, Carre M. Microtubule-targeted agents: When mitochondria become essential to chemotherapy. Biochim Biophys Acta 2011;1807:679-88.
51. Schmitt C, Lowe S. Apoptosis and therapy. J Pathol 1999;187:127-37.
52. Schwab M. MYCN in neuronal tumours. Cancer Lett 2004;204:179-87.
53. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80.
54. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
55. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003;18:1-6.
56. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998;1:949-57.
57. Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 1998;12:2434-42.
58. Tewey K, Rowe T, Yang L, Halligan B, Liu L. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-8.
59. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 1993;53:5269-73.
60. Vogelstein B, Lane D, Levine A. Surfing the p53 network. Nature 2000;408:307-10.
61. Vousden K. p53: death star. Cell 2000;103:691-4.
62. Wozniak A, Ross W. DNA damage as a basis for 49-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-Dglucopyranoside) (etoposide) cytotoxicity. Cancer Res 1983;43:120-4.
63. Xiao J, Lin H, Luo X, Wang Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 2011;30:524-32.
64. Yang L, Rowe T, Liu L. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res 1985;45:5872-6.
65. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12: 2422-33.
66. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405-13.